Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN NASDAQ:LNSR NASDAQ:PASG NASDAQ:SYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$5.45-6.4%$6.22$3.25▼$13.50$74.37M0.91157,441 shs114,659 shsLNSRLENSAR$5.60-0.4%$5.71$5.06▼$13.47$68.03M0.8753,852 shs47,377 shsPASGPassage Bio$5.62-6.3%$6.66$3.93▼$20.00$19.25M1.4147,327 shs34,782 shsSYRASyra Health$0.51-0.3%$0.42$0.05▼$0.70$7.04M3.0846,219 shs29,302 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-6.36%-16.92%-23.88%+1.68%+35.57%LNSRLENSAR-0.36%-3.45%+3.90%-52.54%-58.55%PASGPassage Bio-6.33%-2.60%+36.41%-33.10%-41.82%SYRASyra Health-0.29%-7.55%+13.00%+465.00%+414.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$5.45-6.4%$6.22$3.25▼$13.50$74.37M0.91157,441 shs114,659 shsLNSRLENSAR$5.60-0.4%$5.71$5.06▼$13.47$68.03M0.8753,852 shs47,377 shsPASGPassage Bio$5.62-6.3%$6.66$3.93▼$20.00$19.25M1.4147,327 shs34,782 shsSYRASyra Health$0.51-0.3%$0.42$0.05▼$0.70$7.04M3.0846,219 shs29,302 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene-6.36%-16.92%-23.88%+1.68%+35.57%LNSRLENSAR-0.36%-3.45%+3.90%-52.54%-58.55%PASGPassage Bio-6.33%-2.60%+36.41%-33.10%-41.82%SYRASyra Health-0.29%-7.55%+13.00%+465.00%+414.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 2.71Moderate Buy$33.25510.09% UpsideLNSRLENSAR 2.33Hold$10.0078.57% UpsidePASGPassage Bio 2.14Hold$13.25135.77% UpsideSYRASyra Health 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SYRA, CLNN, LNSR, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026CLNNClene Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)5/8/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026CLNNClene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/4/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/22/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026LNSRLENSAR Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$21.00 ➝ $7.004/21/2026PASGPassage Bio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$21.00 ➝ $7.004/21/2026PASGPassage Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$30.00 ➝ $15.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$200K348.26N/AN/A($1.62) per share-3.36LNSRLENSAR$58.44M1.16N/AN/A($2.18) per share-2.57PASGPassage BioN/AN/AN/AN/A$5.90 per shareN/ASYRASyra Health$7.98M0.88N/AN/A$0.62 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$26.17M-$3.20N/AN/AN/A-25,009.70%N/A-137.98%8/13/2026 (Estimated)LNSRLENSAR-$34.28M-$0.58N/AN/AN/A50.94%-183.19%42.26%8/6/2026 (Estimated)PASGPassage Bio-$45.52M-$11.84N/AN/AN/AN/A-150.88%-59.78%7/30/2026 (Estimated)SYRASyra Health-$2.94M-$0.02N/AN/AN/A-54.90%-131.94%-99.19%8/6/2026 (Estimated)Latest SYRA, CLNN, LNSR, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CLNNClene-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million5/12/2026Q1 2026PASGPassage Bio-$2.7640-$2.36+$0.4040-$2.36N/AN/A5/8/2026Q1 2026LNSRLENSAR$0.1850$1.56+$1.3750N/A$13.40 million$13.43 million3/31/2026Q4 2025LNSRLENSAR-$0.10-$0.12-$0.02-$0.12$20.30 million$16.03 million3/12/2026Q4 2025CLNNClene-$0.74-$0.88-$0.14-$0.88$0.03 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/ALNSRLENSARN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ASYRASyra HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.941.93LNSRLENSARN/A2.381.08PASGPassage BioN/A1.731.73SYRASyra HealthN/A4.634.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%LNSRLENSAR40.15%PASGPassage Bio53.48%SYRASyra Health4.75%Insider OwnershipCompanyInsider OwnershipCLNNClene28.30%LNSRLENSAR66.00%PASGPassage Bio4.90%SYRASyra Health24.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene10012.78 million9.16 millionNo DataLNSRLENSAR11012.10 million4.12 millionOptionablePASGPassage Bio1303.21 million3.05 millionNo DataSYRASyra Health7813.84 million10.16 millionNot OptionableSYRA, CLNN, LNSR, and PASG HeadlinesRecent News About These CompaniesSyria pushes to gain closer ties with Western powers as it reaches meetings with G7, NATO, and WHOMay 23, 2026 | msn.comSyra Health Delivers its First Profitable Quarter in Q1 2026, Expands Margins and Strengthens Financial PositionMay 7, 2026 | prnewswire.comSyra Health To Announce First Quarter 2026 Financial ResultsApril 30, 2026 | prnewswire.comSyra Health Wins Innovation of the Year and BioCrossroads Life Sciences Innovation Award at the 2026 TechPoint Mira AwardsApril 28, 2026 | prnewswire.comSyra Health and Nora Mental Health Announce Telehealth Partnership to Expand Access to Mental and Behavioral Health Services Across IndianaApril 2, 2026 | prnewswire.comSyria’s health minister says Decree 68 will boost staff stability, care qualityMarch 21, 2026 | sana.sySSyra Health Posts Strong FY2025 Results with 157% Population Health Growth and 76% Net Loss Reduction: Targets Profitability by Year-End 2026March 12, 2026 | prnewswire.comSyra Health To Announce Fourth Quarter and Full Year 2025 Financial ResultsMarch 5, 2026 | prnewswire.comSyria launches EU-, WHO-backed projects to boost primary healthcareFebruary 25, 2026 | sana.sySSyria launches health plan to boost medical services in newly liberated areasJanuary 28, 2026 | sana.sySSyria, Turkey discuss expanded health cooperationJanuary 26, 2026 | sana.sySSyria’s Health Ministry delivers 20 dialysis machines to Raqqa hospitalJanuary 25, 2026 | sana.sySSyria declares health emergency over in Aleppo, Raqqa after army gains groundJanuary 25, 2026 | trtworld.comTSlone Partners Places Proven C-Suite Leader and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer at Syra HealthJanuary 21, 2026 | marketwatch.comSyria’s Minister of Higher Education, WHO discuss cooperation to support health sectorJanuary 21, 2026 | sana.sySSyria strengthens healthcare services, expands international partnerships in 2025January 5, 2026 | sana.sySSyria and UAE partner to boost emergency health preparednessJanuary 5, 2026 | sana.sySSyra Health Appoints Gregory Alexander as New CEODecember 18, 2025 | tipranks.comSyra Health Appoints Healthcare Executive and Former U.S. Marine Gregory R. Alexander as Chief Executive Officer to Drive GrowthDecember 18, 2025 | prnewswire.comHealth Ministry, UNICEF explore cooperation in health sectorDecember 1, 2025 | sana.sySNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSYRA, CLNN, LNSR, and PASG Company DescriptionsClene NASDAQ:CLNN$5.45 -0.37 (-6.36%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$5.46 +0.01 (+0.11%) As of 06/5/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.LENSAR NASDAQ:LNSR$5.60 -0.02 (-0.36%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$5.61 +0.01 (+0.18%) As of 06/5/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Passage Bio NASDAQ:PASG$5.62 -0.38 (-6.33%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$5.62 +0.00 (+0.09%) As of 06/5/2026 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Syra Health NASDAQ:SYRA$0.51 0.00 (-0.29%) As of 06/5/2026 03:59 PM EasternSyra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
